[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100597745":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":11,"centralContacts":29,"locations":35,"responsibleParty":50,"collaborators":11,"id":54,"slug":11,"hasResults":55,"nctId":56,"briefTitle":57,"officialTitle":57,"acronym":11,"eligibilityCriteria":58,"healthyVolunteers":55,"sex":59,"minAge":60,"maxAge":11,"enrollmentInfo":61,"targetDuration":11,"studyType":64,"phases":65,"briefSummary":67,"conditions":68,"keywords":11,"overallStatus":70,"whyStopped":11,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":80},{"fullName":5,"class":6},"Sichuan Cancer Hospital and Research Institute","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Control Group","ACTIVE_COMPARATOR",null,[13],"Drug: Control: gemcitabine, cisplatin, tirelizumab",{"label":15,"type":16,"description":11,"interventionNames":17},"Experimental group","EXPERIMENTAL",[18],"Drug: Experimental: gemcitabine, cisplatin, tirelizumab and radiotherapy",[20,25],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":11},"DRUG","Control: gemcitabine, cisplatin, tirelizumab","PD-1 inhibitors combined with chemotherapy",[9],{"type":21,"name":26,"description":27,"armGroupLabels":28,"otherNames":11},"Experimental: gemcitabine, cisplatin, tirelizumab and radiotherapy","PD-1 inhibitors combined with chemoradiotherapy",[15],[30],{"name":31,"role":32,"phone":33,"phoneExt":11,"email":34},"Lu Li","CONTACT","13882258173","lilu_mm@163.com",[36],{"facility":5,"status":11,"city":37,"state":38,"zip":39,"country":40,"countryCode":41,"cosmosGeoPoint":42,"geoPoint":47,"contacts":48},"Chengdu","Sichuan","610041","China","CN",{"type":43,"coordinates":44},"Point",[45,46],104.06667,30.66667,{"lat":46,"lon":45},[49],{"name":31,"role":32,"phone":33,"phoneExt":11,"email":34},{"type":51,"investigatorFullName":52,"investigatorTitle":53,"investigatorAffiliation":5,"oldNameTitle":11,"oldOrganization":11},"PRINCIPAL_INVESTIGATOR","Yangkun Luo","Director","100597745",false,"NCT07062484","A Real-world Study of the Efficacy and Safety of PD-1 Inhibitors Combined With Chemoradiotherapy in Lung Metastatic Nasopharyngeal Carcinoma","Inclusion Criteria:\n\n1. age of at least 18 years;\n2. Karnofsky Performance Status (KPS) ≥60;\n3. histologically confirmed nasopharyngeal squamous carcinoma;\n4. metastatic disease after primary standard treatment (patients who had metastatic diseases over six months after treatment);\n5. at least 1 measurable metastatic lesions in lung or mediastinal or pleura (imaging for distant metastases with FDG-PET\u002FCT or chest\u002Fabdomen CT with contrast);\n6. adequate renal , liver and bone marrow function.\n\nExclusion Criteria:\n\n1. previous treatment with an immune checkpoint inhibitor;\n2. recurrent disease;\n3. previous systemic chemotherapy for metastatic disease;\n4. symptomatic central nervous system metastases;\n5. a history of non-infectious pneumonitis that required glucocorticoids, or active autoimmune disease;\n6. severe organ dysfunction or not suitable for chemoradiotherapy;\n7. individuals that had serious kidney, heart, blood, nervous system, or liver diseases or psychiatric disorders;\n8. individuals that had taken part in any other clinical trials testing other drugs within 3 months of the present study;\n9. other patients whom researchers deemed unsuitable to participate in the study.","ALL","18 Years",{"count":62,"type":63},600,"ESTIMATED","INTERVENTIONAL",[66],"NA","This study is a retrospective real-world study. In this study, we plan to collect the clinical data of lung metastatic nasopharyngeal carcinoma patients who received PD-1 inhibitors and chemotherapy combined with or without radiotherapy.",[69],"Lung Metastatic Nasopharyngeal Carcinoma","NOT_YET_RECRUITING","2025-07-10",{"date":73,"type":74},"2025-07-14","ACTUAL",{"date":76,"type":63},"2025-07",{"date":78,"type":63},"2025-12",{"name":5,"class":6},1]